KIORA PHARMACEUTICALS INC 8-K

What Happened Kiora Pharmaceuticals, Inc. (KPRX) filed a Form 8-K on March 25, 2026 to announce its financial results for the year ended December 31, 2025 and to provide an update on its clinical development progress. The company issued a press release containing these results and the development update, which is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: March 25, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: year ended December 31, 2025.
• Press release attached as Exhibit 99.1; Cover Page Interactive Data File included as Exhibit 104.
• Form 8-K signed by Melissa Tosca, Chief Financial Officer.

Why It Matters This 8-K furnishes Kiora’s latest annual financial results (earnings/revenue and related metrics will be in the attached press release) and an update on clinical programs—information material to investors assessing the company’s financial health and drug-development progress. Investors should review the attached press release (Exhibit 99.1) for the specific financial figures, cash position, and clinical milestone details.